The approval of a new oral postexposure prophylaxis for COVID-19 marks a significant advancement in the disease's prevention ...

FDA approves ensitrelvir for COVID-19 postexposure prophylaxis following phase 3 data showing efficacy against Omicron symptoms. The FDA recently approved ensitrelvir (Xocova; Shionogi), an ...

REGEN-COV consists of 2 potent, virus-neutralizing antibodies that bind noncompetitively to the receptor binding domain of the SARS-CoV-2 spike protein. The Food and Drug Administration (FDA) has ...

The FDA has approved the oral antiviral Xocova (ensitrelvir) for postexposure prophylaxis of COVID-19 in adults and adolescents.

Postexposure prophylaxis with nirmatrelvir-ritonavir for five or 10 days does not reduce the risk for symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a ...

Postexposure prophylaxis with bamlanivimab plus etesevimab is not a substitute for vaccination against COVID-19. The Food and Drug Administration (FDA) has expanded the Emergency Use Authorization ...

In a study conducted at the University of Washington, USA, the researchers assert that post-exposure prophylaxis with monoclonal antibodies could improve the clinical outcomes and health system costs ...

In a recent study posted to the medRxiv* preprint server, researchers determined evidence for post-exposure vaccination in reducing the mortality rate of coronavirus disease 2019 (COVID-19).

The U.S. Food and Drug Administration has approved Xocova (ensitrelvir), an oral antiviral, for postexposure prophylaxis (PEP ...